Validation of neuromuscular blocking agent use in acute respiratory distress syndrome: a meta-analysis of randomized trials.

ABSTRACT:

Background

We aimed to synthesize up-to-date trials to validate the effects of neuromuscular blocking agent (NMBA) use in patients with moderate-to-severe acute respiratory distress syndrome (ARDS).

Methods

Several databases including PubMed, EMBASE, Web of Science, and Cochrane Central Register were searched up to November 14, 2019. All randomized trials investigating the use of NMBAs in patients with moderate-to-severe ARDS and reporting mortality data were included in the meta-analysis. The primary outcome was mortality, and the secondary outcomes were clinical outcomes, including respiratory physiological parameters, incidence of barotrauma, ICU-free days, and ventilation-free days.

Results

A total of 7 trials enrolling 1598 patients were finally included in this

SUBMITTER: Chang W 

PROVIDER: S-EPMC7027110 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature